Gilead ’s Magrolimab, an Investigational Anti-CD47 Monoclonal Antibody, Receives FDA Breakthrough Therapy Designation for Treatment of Myelodysplastic Syndrome

FOSTER CITY, Calif.--(BUSINESS WIRE)--Sep. 15, 2020-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for magrolimab, a...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials